Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN17092 in healthy volunteers
NCT05923424Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REGN17092 in coronavirus disease 2019 (COVID-19) (10 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events at Day 365, Severity of Treatment Emergent Adverse Events at Day 365 and 2 more. Started Nov 2023; status: completed.
02
Drugs
REGN17092
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05923424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923424.